Acadia Pharmaceuticals enters the second half of 2026 with both commercial franchises executing above plan and a pivotal pipeline readout on the horizon. The second quarter delivered 17 percent year-over-year revenue growth on an adjusted basis, driven by DAYBUE's accelerating launch trajectory and NUPLAZID's resilient demand in Parkinson's disease psychosis. Management raised full-year guidance for the second consecutive quarter, now targeting $1.24 to $1.30 billion in total revenue, with DAYBUE's range lifted to $480 to $510 million. The quarter's strategic signal is not the beat itself but the durability it implies: both franchises are compounding at rates that support management's stated ambition of approximately $1.7 billion in annual net sales by 2028.
The investment thesis rests on three variables with distinct market tracking signals. First, DAYBUE's U.S. penetration curve: the primary metric is quarterly net sales progression toward the $480-510 million guidance range, the strategic intent is proving the Rett syndrome franchise can sustain 25-30 percent growth beyond the initial launch phase, and the market signal is whether STIX formulation adoption and expanded sales force coverage translate into consistent quarter-over-quarter growth. Second, NUPLAZID's unit volume trajectory: the primary metric is year-over-year prescription growth in a mature category, the strategic intent is demonstrating that a decade-old asset can still grow through sales force expansion and market deepening, and the market signal is whether the 10 percent adjusted growth rate in Q2 represents a sustainable inflection or a one-time step-up from field force additions. Third, the remlifanserin Phase 2 readout in Alzheimer's disease psychosis: the primary metric is statistical significance on the primary endpoint with a clean safety profile, the strategic intent is validating a potential third franchise in a multi-billion-dollar indication, and the market signal is the binary re-rating that accompanies a positive result versus the compression risk of a miss.
The binary market implications crystallize around the September-October remlifanserin data. A positive Phase 2 outcome with FDA Fast Track designation already in hand would confirm the pipeline optionality that the current valuation underweights, potentially unlocking a sum-of-parts re-rating toward the $1.7 billion 2028 revenue ambition. A negative or ambiguous result would collapse the ADP option value, leaving the equity dependent solely on the two commercial franchises to justify the multiple, a scenario that compresses the stock toward a high-single-digit revenue multiple. The market currently prices limited pipeline success probability; the Q2 commercial overdelivery has not yet forced a reassessment of that embedded skepticism.